M Kathryn Fink Sells 5,220 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the sale, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

M Kathryn Fink also recently made the following trade(s):

• On Monday, May 11th, M Kathryn Fink sold 3,500 shares of Stryker stock. The shares were sold at an average price of $283.45, for a total value of $992,075.00.

Stryker Stock Up 4.3%

Shares of NYSE SYK traded up $12.16 during mid-day trading on Tuesday, hitting $294.74. 3,287,824 shares of the stock traded hands, compared to its average volume of 2,151,943. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a market cap of $112.88 billion, a price-to-earnings ratio of 34.11, a PEG ratio of 1.80 and a beta of 0.80. The stock has a fifty day moving average price of $336.33 and a 200-day moving average price of $353.81.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Institutional Investors Weigh In On Stryker

Institutional investors have recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Stryker in the fourth quarter worth approximately $1,822,272,000. Auto Owners Insurance Co raised its holdings in shares of Stryker by 35,047.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after buying an additional 2,906,448 shares during the period. Wellington Management Group LLP raised its holdings in shares of Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after buying an additional 1,198,665 shares during the period. Corient Private Wealth LLC raised its holdings in shares of Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after buying an additional 1,146,998 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in shares of Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares during the period. 77.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Needham & Company LLC cut their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a research note on Friday, May 1st. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Evercore set a $355.00 price target on Stryker in a research note on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.